Chinese Clinical Oncology

• 综述与讲座 • Previous Articles     Next Articles

Progression of Nab-paclitaxel for pancreatic carcinoma

MEI Kuimin, LIU Xiufeng, QIN Shukui.   

  1. Department of Oncology, PLA Cancer Center, 81 Hospital of PLA, Nanjing 210002, China
  • Received:2014-02-08 Revised:2014-03-12 Online:2014-07-30 Published:2014-07-30
  • Contact: QIN Shukui

Abstract: Pancreatic carcinoma(PC) is one of the most detrimental common digestive malignancies, which is characterized by hidden onset, rapid progression and short course. Chemotherapy is an indispensable treatment approaches for patients with advanced PC. Gemcitabine act as a gold standard drug, but its effect is limited. A new drug, that is Nab-paclitaxel with its unique formulation advantage, has made breakthrough progress in the treatment of advanced PC and has become the new standard chemotherapy drugs for advanced pancreatic carcinoma.

No related articles found!
Viewed
Full text
287
HTML PDF
Just accepted Online first Issue Just accepted Online first Issue
0 0 0 0 0 287

  From Others local
  Times 14 273
  Rate 5% 95%

Abstract
156
Just accepted Online first Issue
0 0 156
  From Others
  Times 155
  Rate 100%

Cited

Web of Science  Crossref   ScienceDirect  Search for Citations in Google Scholar >>
 
This page requires you have already subscribed to WoS.
  Shared   
  Discussed   
No Suggested Reading articles found!